MannKind Corporation: Q1 2014 Form 10-Q Summary
Business context and reporting period
MannKind is a development-stage biopharmaceutical company focused on diabetes therapies and its Technosphere inhalation platform. Its lead candidate, AFREZZA, was under FDA review and had not generated commercial revenue. The filing covers the unaudited quarter ended March 31, 2014, compared with the quarter ended March 31, 2013.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $26.2 million | $26.4 million | Down 1% |
| General and administrative expense | $15.2 million | $10.0 million | Up 52% |
| Total operating expenses | $41.4 million | $36.4 million | Up 14% |
| Loss from operations | $41.4 million | $36.4 million | Loss increased $5.0 million |
| Net loss | $52.1 million | $41.0 million | Loss increased $11.1 million |
| Net loss per share | $0.14 | $0.15 | Improved on a per-share basis |
| Cash used in operating activities | $37.0 million | $32.0 million | Use increased $5.0 million |
There was no meaningful revenue or operating margin because the company had no product sales. Stock-based compensation was $10.9 million, compared with $5.2 million in the prior-year quarter, and depreciation and accretion were $9.4 million, compared with $3.3 million.
| Balance-sheet metric | March 31, 2014 | December 31, 2013 |
|---|---|---|
| Cash and cash equivalents | $35.8 million | $70.8 million |
| Total assets | $224.6 million | $258.6 million |
| Total liabilities | $207.0 million | $289.4 million |
| Stockholders’ equity | $17.5 million | $(30.7) million |
| 2015 senior convertible notes, principal | $100.0 million | $100.0 million |
| 2019 notes, principal outstanding after conversions | $27.5 million | Not comparable in the filing presentation |
| Loan Arrangement with The Mann Group | $49.5 million outstanding | $49.5 million outstanding |
Cash declined by $35.0 million during the quarter. Financing activities provided $3.4 million, primarily from warrant and stock-option exercises, while investing activities used $1.4 million. The company reported cumulative net losses of $2.3 billion and cumulative negative operating cash flow of $1.8 billion since inception.
Material changes versus the prior comparable period
- Net loss increased 27% to $52.1 million, primarily reflecting higher general and administrative costs, increased interest-related costs and a $6.0 million expense associated with conversions of 2019 notes.
- Research and development expense was broadly stable: clinical spending fell $4.1 million following completion of two Phase 3 studies, while manufacturing spending rose $1.4 million in preparation for potential commercialization and stock compensation increased $2.4 million.
- General and administrative expense increased $5.2 million, driven mainly by a $3.4 million increase in stock-based compensation, higher consulting and legal fees, and higher employee compensation.
- Deerfield conversions during the quarter reduced the principal amount of 2019 notes and resulted in the issuance of approximately 16.1 million common shares during the quarter. Common shares outstanding increased from 369.4 million at December 31, 2013 to 386.9 million at March 31, 2014.
- Stockholders’ equity improved from a $30.7 million deficit to $17.5 million of equity, primarily due to debt conversions and related equity issuance rather than operating profitability.
Guidance, outlook, risks and unusual items
- On April 1, 2014, the FDA advisory committee recommended AFREZZA approval by votes of 13-1 for type 1 diabetes and 14-0 for type 2 diabetes. The FDA subsequently extended the PDUFA date to July 15, 2014. Advisory committee recommendations did not constitute FDA approval.
- Management expected existing resources to fund planned operations at least into the third quarter of 2014, but disclosed substantial doubt about the company’s ability to continue as a going concern.
- Additional funding was expected to be necessary through equity or debt issuance, strategic collaboration, licensing, asset sales or other financing. Two $50 million at-the-market equity programs had been established, but no shares had been sold under them as of March 31, 2014.
- Deerfield had purchased $120 million of the potential $160 million of 2019 notes as of quarter-end. The remaining $40 million tranche was conditional on AFREZZA approval and other requirements. On May 6, 2014, after quarter-end, Deerfield purchased $20 million of Tranche B notes.
- The Facility Agreement required cash and cash equivalents, including available Mann Group borrowings, of at least $25 million at each quarter-end. The company had $35.8 million of cash and $30.1 million of available Mann Group borrowings at March 31, 2014.
- Debt and liquidity risks were significant: $100 million of 2015 notes matured in August 2015, 2019 notes bore 9.75% interest, and the Facility Agreement was secured by substantially all assets, including specified intellectual property and facilities.
- Key business risks included failure or delay of FDA approval, manufacturing scale-up, market acceptance and reimbursement, absence of a commercialization partner, competition, intellectual-property disputes, continued operating losses, and potential dilution from debt conversions, warrants and equity offerings.
Most important facts for investors to verify
- Whether AFREZZA received FDA approval by the extended July 15, 2014 PDUFA date and the resulting labeling, post-marketing requirements and commercialization terms.
- Actual cash burn and available liquidity after the May 2014 $20 million Tranche B borrowing.
- Terms and maturity obligations of the 2015 notes, 2019 notes and Tranche B notes, including conversion activity and collateral provisions.
- Progress toward a commercialization collaboration and the company’s ability to access its ATM programs or other financing.
- Manufacturing readiness, FDA facility requirements, supply availability and expected launch expenditures for AFREZZA.
- Potential dilution from additional note conversions, warrants, stock offerings and the increasing share count.